With Aduhelm Out Of The Gate, Biogen Focuses On Clearing Commercial Bottlenecks
PET scans and CSF testing to confirm the presence of amyloid beta, and reimbursement, are expected to be early hurdles for launching aducanumab in Alzheimer's.
You may also be interested in...
The upcoming filing of Lilly's Alzheimer's antibody donanemab dominated the company's second quarter call. Lilly is also developing a new blood test to confirm diagnosis and a second-generation antibody.
The company insists it will reconsider the price of Aduhelm if the market turns out to be larger than Biogen anticipates, but big price reductions for branded drugs are rare.
Reimbursement, health policy and medical experts predicted a slow rollout ahead for Biogen's new Alzheimer's treatment at a public meeting sponsored by ICER.